| Source: Research and Markets
Dublin, April 25, 201six (GLOBE NEWSWIRE) — Research and Markets has actually announced the addition of the “Kind 2 Diabetes Mellitus Therapeutics in Asia-Pacific Markets to 2021 – Increasing Usage of Newer Therapies and Expanding Treatment Population to Urge Robust Growth” report to their offering.
Diabetes mellitus is a group of metabolic diseases characterized by chronic hyperglycemia – higher blood glucose levels – that outcomes from defects in insulin secretion, insulin action, or a combination of these. This chronic hyperglycemia is associated along with long term damage, dysfunction and failure of multiple organs including the eyes, kidneys, nerves, heart and blood vessels.
The vast majority of diabetes mellitus patients can easily be classified as having either Kind 1 Diabetes Mellitus (T1DM) or Kind 2 Diabetes Mellitus (T2DM). About 85-95% of every one of diabetics have actually T2DM.
T2DM treatment has actually been revolutionized in the past decade, especially along with the increased usage of Brand-new therapies. The marketed products landscape comprises a wide range of treatment options, including biguanide (metformin), sulfonylureas, thiazolidinediones, GLP-1 receptor agonist, DPP-4 inhibitor, SGLT-2 inhibitor, and insulin therapies.
Nevertheless, substantial unmet necessity remains for products that can easily supply much better glycemic regulate also as the prevention and cure of diabetic complications, such as diabetic nephropathy, retinopathy, and cardio disease.
Scope
The current T2DM in the Asia-Pacific (APAC) market consists of novel products, including Jardiance – a SGLT-2 inhibitor; Victoza – a GLP-1 receptor agonist; and Galvus – a DPP-4 inhibitor.
– Just what are the competitive benefits of the existing novel drugs?
With over 500 energetic pipeline molecules, a lot of of the late-phase investigational drug candidates are being evaluated, featuring improved dosing routines and administration routes, in comparison to currently marketed products and combination therapies.
– Which classes of novel drugs are a lot of prominent within the pipeline?
– Is there tough potential for the pipeline to handle unmet calls for within the T2DM market?
Analysis of clinical trials, because 2006, identified that the failure paces of T2DM molecules were highest in Phase II, at 54%, along with the total attrition price for T2DM at 82.6%.
– Exactly how do failure paces vary by product phase of development, molecule type, and mechanism of action?
– Exactly how do others factors, such as standard trial duration and trial dimension motivate the costs and risks associated along with product development?
Over the 2014-2021 forecast period, the T2DM therapeutics in the APAC markets is expected to enhance in value at a CAGR of 7.7%, from $6.07 billion to over $10.2 billion.
Key Topics Covered:
1 Table of Contents
1.1 List of Tables
1.2 List of Figures
2 Introduction
2.1 health problem Overview
2.2 Classification
2.3 Symptoms
2.4 Etiology
2.five Pathophysiology
2.six Epidemiology
2.7 Prognosis
2.8 Co-morbidities and Complications
2.9 Diagnosis
2.10 Assessing Treatment Effectiveness
2.11 Treatment
2.11.1 Non-insulin T2DM Therapies
2.11.2 Insulin T2DM Therapies
2.12 Treatment Segments
2.12.1 Non-insulin therapies
2.12.2 Insulin Therapies
3 Marketed Products
3.1 Overview
3.2 Biguanides
3.2.1 Metformin
3.3 Sulfonylureas
3.4 Thiazolidinediones
3.4.1 Pioglitazone
3.five GLP-1 receptor agonists
3.5.1 Byetta (exenatide)
3.5.2 Bydureon (exenatide)
3.5.3 Victoza (liraglutide)
3.5.4 Lyxumia (lixisenatide)
3.5.five Tanzeum (albiglutide)
3.5.six Trulicity (dulaglutide)
3.six DPP-4 Inhibitors
3.6.1 Januvia/Glactiv (sitagliptin)
3.6.2 Galvus (vildagliptin)
3.6.3 Onglyza (saxagliptin)
3.6.4 Trazenta (linagliptin)
3.6.five Zafatek (trelagliptin succinate)
3.6.six Marizev (omarigliptin)
3.7 SGLT-2 Inhibitors
3.7.1 Forxiga (dapagliflozin)
3.7.2 Invokana (canagliflozin)
3.7.3 Jardiance (empagliflozin)
3.8 Insulin Therapies
3.8.1 Lantus (insulin glargine)
3.8.2 Levemir (insulin detemir)
3.8.3 Tresiba (insulin degludec)
3.8.4 Toujeo/ Lantus XR (insulin glargine)
3.9 Marketed Products Heat Maps
4 Pipeline
4.1 Overview
4.2 Pipeline Distribution by phase of Development, Molecule Kind and Routine Type
4.3 Pipeline Distribution by Molecular Target
4.4 Clinical Trial Landscape
4.five Promising Pipeline Molecules
4.5.1 NN-953five (subcutaneous semaglutide) and OG-217SC (oral semaglutide) – Novo Nordisk
4.5.2 ITCA 650 – Intarcia Therapeutics
4.5.3 Ertugliflozin – Pfizer
4.six Pipeline Products Heat Map
5 Market Forecast to 2021
5.1 Geographical Markets
5.2 Asia-Pacific Markets
5.3 China
5.4 India
5.five Australia
5.six Japan
5.7 Drivers and Barriers for the T2DM Therapeutics Market
6 Strategic Consolidations
6.1 Licensing Deals
6.1.1 AbbVie Collaborates along with Halozyme Therapeutics to Bank on its ENHANZE Technology
6.1.2 Janssen Collaborates along with Halozyme Therapeutics to Bank on its ENHANZE Technology
6.1.3 Emisphere Signs Licensing Agreement along with Novo Nordisk to make Oral Formulations Targeting Metabolic Indications
6.1.4 Amunix Announces Exclusive Agreements along with Naia to make GLP-1 and GLP-2 XTEN Products
6.2 Co-progress Deals
6.2.1 Intarcia Therapeutics Enters into in to Co-progress Agreement along with Servier for ITCA 650 (DUROS delivery exenatide)
6.2.2 Merck Enters into in to Co-progress Agreement along with Pfizer for ertugliflozin
6.2.3 AstraZeneca Enters into in to Research Agreement along with Inserm
6.2.4 Intarcia Therapeutics Enters into in to Co-progress Agreement along with Numab
6.2.five AstraZeneca Enters into in to Co-progress Agreement along with Bristol-Myers Squibb
7 Appendix
Companies Mentioned
– AbbVie
– Amunix
– AstraZeneca
– Bristol-Myers Squibb
– Emisphere
– Halozyme Therapeutics
– Intarcia Therapeutics
– Janssen
– Merck
– Naia
– Novo Nordisk
– Numab
– Pfizer
For much more short article visit http://ift.tt/1NL0i4w
CONTACT: Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hrs Call 1-917-300-0470
For U.S./can easily Toll Free Call 1-800-526-8630
For GMT Office Hrs Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Related Articles
other press releases by Research and Markets
CONTACT: Research and Markets Laura Wood, Senior Manager press@researchandmarkets.com For E.S.T Office Hrs Call 1-917-300-0470 For U.S./can easily Toll Free Call 1-800-526-8630 For GMT Office Hrs Call +353-1-416-8900 U.S. Fax: 646-607-1907 Fax (outside U.S.): +353-1-481-1716
LOGO URL | Copy the link here
Formats available:
